Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by BioTeckon Sep 08, 2022 3:22pm
255 Views
Post# 34950274

RE:Treat 1% of 1.6M U.S. Diabetes 1 Patients

RE:Treat 1% of 1.6M U.S. Diabetes 1 Patients This info has been published many many moons ago by SVA and brought up in nearly every presentation since. Google Sernova Payor survey if you don't believe me. Nothing in that presentation was new except patient 7 selected and due for implant of larger pouch in mid october. Results not expected till mid next year assuming they actually hit the timelines. THey've been talking about patient 7 for over a year now. Share price is going nowhere but down based on what I heard today. Nothing in the nearterm to lift it that the company is doing or planning other than warrants expiring. Most of those people will likely cash in and sell those as well. You could sit on your shares for a couple years and hope all the experiments go well and all the competitions don't. Unlikely scenario however. The space is heating up and all we have is a piece of plastic. If someone came out with a new device design today, they could be in the clinic testing it before sernova even gets the Evotec cells in humans. I guess that's the speed you run at when you're a micro managing one man show.
<< Previous
Bullboard Posts
Next >>